Molecular simulation studies of human coagulation factor VIII C domain-mediated membrane binding

Summary

The C-terminal C domains of activated coagulation factor VIII (FVIIIa) are essential to membrane binding of this crucial coagulation cofactor protein. To provide an overall membrane binding mechanism for FVIII, we performed simulations of membrane binding through coarsegrained molecular dynamics simulations of the C1 and C2 domain, and the combined C-domains (C1+C2). We found that the C1 and C2 domain have different membrane binding properties. The C1 domain uses hydrophobic spikes 3 and 4, of its total of four spikes, as major loops to bind the membrane, whereas all four of its hydrophobic loops of the C2 domain appear essential for membrane binding. Interestingly, in the C1+C2 system, we observed cooperative binding of the C1 and C2 domains such that all four C2 domain spikes bound first, after which all four loops of the C1 domain inserted into the membrane, while the net binding energy was higher than that of the sum of the isolated C domains. Several residues, mutations of which are known to cause haemophilia A, were identified as key residues for membrane binding. In addition to these known residues, we identified residues from the C1 and C2 domains, which are involved in the membrane binding process, that have not been reported before as a cause for haemophilia A, but which contribute to overall membrane binding and which are likely candidates for novel causative missense mutations in haemophilia A.

Keywords

Coarse-Grained Molecular Dynamics (CGMD) - Coagulation FVIII - C domains - membrane - haemophilia A

• References

• 1 Lenting PJ. et al. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-3996.
• 2 Saenko E. et al. Comparison of the properties of phospholipid surfaces formed on HPA and L1 biosensor chips for the binding of the coagulation factor VIII. J Chromatogr A 2001; 921: 49-56.
• 3 Novakovic VA. et al. Membrane-binding properties of the Factor VIII C2 domain. Biochem J 2011; 435: 187-196.
• 4 Liu Z. et al. Trp2313-His2315 of factor VIII C2 domain is involved in membrane binding: structure of a complex between the C2 domain and an inhibitor of membrane binding. J Bbiol Chem 2010; 285: 8824-8829.
• 5 Lu J. et al. A membrane-interactive surface on the factor VIII C1 domain cooperates with the C2 domain for cofactor function. Blood 2011; 117: 3181-3189.
• 6 Takeshima K. et al. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost 2003; 89: 788-794.
• 7 Pratt KP. et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402: 439-442.
• 8 Eaton D. et al. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
• 9 van Dieijen G. et al. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442.
• 10 van Dieijen G. et al. Assembly of the intrinsic factor X activating complex--interactions between factor IXa, factor VIIIa and phospholipid. Thromb Haemost 1985; 53: 396-400.
• 11 Gilbert GE, Arena AA. Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine. The J Biol Chem 1996; 271: 11120-11125.
• 12 Foster PA. et al. A synthetic factor VIII peptide of eight amino acid residues (1677–1684) contains the binding region of an anti-factor VIII antibody which inhibits the binding of factor VIII to von Willebrand factor. Thrombosis and haemostasis 1990; 63 (03) p. 403-406.
• 13 Gilbert GE. et al. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem 2002; 277: 6374-6381.
• 14 Stace CL, Ktistakis NT. Phosphatidic acid- and phosphatidylserine-binding proteins. Biochim Biophys Acta 2006; 1761: 913-926.
• 15 Saenko EL. et al. Factor VIII – novel insights into form and function. Br J Haematol 2002; 119: 323-331.
• 16 Ngo JC. et al. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008; 16: 597-606.
• 17 Shen BW. et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008; 111: 1240-1247.
• 18 Svensson LA. et al. Evaluation of the metal binding sites in a recombinant coagulation factor VIII identifies two sites with unique metal binding properties. Biol Chem 2013; 394: 761-765.
• 19 Stoilova-McPhie S. et al. Domain organization of membrane-bound factor VIII. Biopolymers 2013; 99: 448-459.
• 20 Autin L. et al. Molecular models of the procoagulant factor VIIIa-factor IXa complex. J Thromb Haemost 2005; 03: 2044-2056.
• 21 Stoilova-McPhie S. et al. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 2002; 99: 1215-1223.
• 22 Nicolaes GA. et al. Mutations in a potential phospholipid binding loop in the C2 domain of factor V affecting the assembly of the prothrombinase complex. Blood Coagul Fibrinolysis 2000; 11: 89-100.
• 23 Kemball-Cook G. et al. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res 1998; 26: 216-219.
• 24 Kim SW. et al. Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis. Biochemistry 2000; 39: 1951-1958.
• 25 d’Oiron R. et al. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. Blood 2004; 103: 155-157.
• 26 Tagariello G. et al. Experience of a single Italian center in genetic counseling for hemophilia: from linkage analysis to molecular diagnosis. Haematologica 2000; 85: 525-529.
• 27 Spiegel PC. et al. Surface-exposed hemophilic mutations across the factor VIII C2 domain have variable effects on stability and binding activities. J Biol Chem 2004; 279: 53691-53698.
• 28 Ingolfsson HI. et al. The power of coarse-graining in biomolecular simulations. WIRES Comput. Mol Sci 2014; 04: 225-248.
• 29 Krieger EG. et al. Increasing the precision of comparative models with YASARA NOVA--a self-parameterizing force field. Proteins 2002; 47: 393-402.
• 30 Joosten RP. et al. A series of PDB related databases for everyday needs. Nucleic Acids Res 2011; 39 Database issue D411-419.
• 31 Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983; 22: 2577-2637.
• 32 Periole X. et al. Combining an elastic network with a coarse-grained molecular force field: structure, dynamics and intermolecular recognition. J Chem Th Comp 2009; 05: 2531-2543.
• 33 Marrink SJ. et al. The MARTINI force field: coarse grained model for biomolecular simulations. J Phys Chem B 2007; 111: 7812-7824.
• 34 Monticelli L. et al. The MARTINI coarse grained forcefield: extension to proteins. J Chem Theory Computation 2008; 04: 819-834.
• 35 Meems H. et al. Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity. Blood 2009; 114: 3938-3946.
• 36 Ettinger RA. et al. HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Haemophilia 2010; 16: 44-55.
• 37 Gilbert GE. et al. Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity. Blood 2012; 120: 1923-1932.
• 38 Wakabayashi H. et al. Factor VIII lacking the C2 domain retains cofactor activity in vitro. J Biol Chem 2010; 285: 25176-25184.
• 39 Graw J. et al. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 2005; 06: 488-501.
• 40 Zwaal RF. et al. Membrane asymmetry and blood coagulation. Nature 1977; 268: 358-360.
• 41 Engelke H. et al. FVIII binding to PS membranes differs in the activated and non-activated form and can be shielded by annexin A5. J Phys Chem B 2011; 115: 12963-12970.
• 42 Heemskerk JW. et al. Platelet activation and blood coagulation. Thromb Hae-most 2002; 88: 186-193.
• 43 Bock PE. et al. Exosites in the substrate specificity of blood coagulation reactions. J Thromb Haemost 2007; 05 (Suppl. 01) 81-94.
• 44 Heymann JB. et al. Characterization of electrostatic and nonelectrostatic components of protein--membrane binding interactions. Biochemistry 1996; 35: 2717-2725.
• 45 Gilbert GE, Drinkwater D. Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine. Biochemistry 1993; 32: 9577-9585.
• 46 Foster PA. et al. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 1990; 75: 1999-2004.
• 47 d’Oiron R. et al. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors. Semin Hematol 2006; 43 (Suppl. 01) (01) S3-9.
• 48 Yesylevskyy SO. et al. Polarizable water model for the coarse-grained MARTINI force field. PLoS Comput Biol 2010; 06: e1000810.
• 49 Djurre H. et al. Improved Parameters for the Martini Coarse-Grained Protein Force Field. J. Chem. Theory Comput 2013; 09: 687-697.
• 50 Schatz SM. et al. Mutation of the surface-exposed amino acid Trp2313 to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional protein. Br J Haematol 2004; 125: 629-637.